Distributor Login
Don’t have an account ? Register Now
Distributor Registration
First Name*:
Last Name*:
Company*:
Email*:
Password*:
(6 charactes minimum, numbers & letters)
Verify Password*:
Fill out the form to download brochures
System layout brochure
EarlySense All-in-One brochure
EarlySense Safety brochure
EarlySense Vitals brochure
Selected case studies booklet
White paper
Clinical & economic benefits
I would like more information on
First Name*:
Last Name*:
Position*:
Institute:
Email*:
Phone:
Mailing address:
Mailing address (line 2):
Country*
City:
State:
Zip:
Comments:
June 12, 2017
AAMI Coalition Marks Three Years of Advancing Continuous Monitoring for Patients Being Treated with Opioid Pain Therapy

 

Contact-Free Continuous Monitoring Poised to Become New Standard of Care

 

Austin, TX – June 12, 2017 – Prominent healthcare leaders and innovators met over the weekend at the 2017 AAMI Conference and Expo in Austin, Texas. The event explored opportunities and advances in healthcare technology, including continuous monitoring of patients being treated with opioid pain therapy, who may be at an increased risk of developing respiratory depression.

 

“Since 2014, the AAMI Foundation’s National Coalition to Promote Continuous Monitoring of Patients on Opioids has worked tirelessly to advance continuous monitoring as part of the clinical plan to prevent unnecessary deaths that result from opioid induced respiratory depression,” said Marilyn Neder Flak, Executive Director of AAMI.  “We’ve hosted numerous educational events, published data and supported partnerships to make healthcare providers aware of this issue and the various technologies available to help reduce preventable deaths.”

 

Every year, an estimated 3,000-5,000 patients die in U.S. hospitals from opioid induced respiratory depression, which often strikes patients in low-risk areas of the hospital where patient monitoring is typically limited to nursing rounds. This is defined as a nursing professional visiting the patient once every 4-8 hours to perform vital signs checks, and overall wellness checks on patients.  The ECRI Institute recently cited opioid administration and monitoring in acute care as one of the top safety concerns in its 2017 Patient Safety Guidelines.

 

“Clinical evidence from early adopters and published literature shows that continuous monitoring can reduce in-hospital unplanned morbidity, including opioid induced respiratory depression, and is well on track to become the standard of care on general care floors,” said Dr. Frank Overdyk, Chairman of the National Coalition and AAMI board member. “Rather than improve our response to critical events after they have occurred, continuous monitoring allows clinicians to detect patient deterioration early, and institute treatments that improve outcomes and reduce preventable harm

“As one of the founding partners of the Coalition, EarlySense is proud to support healthcare facilities in improving patient care and outcomes by providing the market’s most advanced continuous monitoring solutions,” said Tim O’Malley, EarlySense President. “Over the past several years, adoption of our technology has grown considerably, helping to save lives and reduce overall healthcare costs. We are pleased to continue working with our coalition partners, customers, industry partners and advocates to help realize the vision of making continuous monitoring the new standard of patient care. Continuous monitoring allows thousands of data points to be collected and analyzed, providing valuable insight into a patient’s status long before an acute event can develop.”

 

About AAMI

The AAMI Foundation is a 501(c)3 charitable organization whose primary mission is to serve the public welfare and to promote the safe adoption and safe use of healthcare technology. It does this through the work of safety initiatives, the distribution of scholarships to students, global outreach initiatives, and awards for excellence.  http://www.aami.org

 

About EarlySense

EarlySense provides contact-free, continuous monitoring solutions for the medical and consumer digital health markets. EarlySense’s patented sensor and advanced algorithms monitor and analyze cardiac, respiratory and motion parameters. Used in hospitals and healthcare facilities worldwide, EarlySense assists clinicians in early detection of patient deterioration, helping to prevent adverse events, including code blues, preventable ICU transfers, patient falls and pressure ulcers.

LIVE by EarlySense is the first home health and sleep monitor powered by medically-proven, contact-free, continuous monitoring technology. The company’s OEM technology is also at the core of wellness and sleep products marketed by international partners including Samsung, Beurer and iFit. EarlySense was founded in 2004 and has offices in Waltham, MA, and Ramat Gan, Israel.

 

For more information, please visit www.earlysense.com and www.livebyearlysense.com.

Follow EarlySense on LinkedInTwitter and Facebook.

Follow LIVE by EarlySense on Facebook and Twitter.